scholarly article | Q13442814 |
P50 | author | Irene Luque | Q28324695 |
Francisco Conejero-Lara | Q30158387 | ||
Carmelo Luci | Q57586696 | ||
Selma Bekri | Q59683772 | ||
Veronique Braud | Q70876532 | ||
Frédéric Martinon | Q87259722 | ||
P2093 | author name string | Nathalie Dereuddre-Bosquet | |
Roger Le Grand | |||
Bin Su | |||
Christiane Moog | |||
Pedro L Mateo | |||
Pierre Bourdely | |||
Sara Crespillo | |||
Fabienne Anjuère | |||
P2860 | cites work | SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling | Q27860614 |
Nucleotide sequence of the AIDS virus, LAV | Q28286313 | ||
Structural studies of receptor binding by cholera toxin mutants | Q28485707 | ||
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection | Q29619099 | ||
HIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants. | Q30341167 | ||
Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates | Q33750130 | ||
Which Antibody Functions are Important for an HIV Vaccine? | Q33772637 | ||
Mucosal immunity and tolerance: relevance to vaccine development | Q33776172 | ||
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope | Q34078521 | ||
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates | Q34096530 | ||
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers | Q34206463 | ||
Mucosal immunity and vaccines | Q34409172 | ||
Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine | Q35113308 | ||
Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women | Q35545581 | ||
Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac2 | Q35867976 | ||
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques | Q36366154 | ||
Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens | Q36747750 | ||
Role of HIV membrane in neutralization by two broadly neutralizing antibodies | Q37453499 | ||
Sublingual mucosa: A new vaccination route for systemic and mucosal immunity | Q37829073 | ||
Sublingual vaccination | Q37832086 | ||
B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells. | Q38033664 | ||
Molecular and Physicochemical Factors Governing Solubility of the HIV gp41 Ectodomain. | Q38828082 | ||
Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques | Q39265150 | ||
Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. | Q39684787 | ||
Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition | Q39943795 | ||
Amplified ELISPOT assay for the detection of HIV-specific antibody-secreting cells in subhuman primates | Q41109989 | ||
Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier | Q41143183 | ||
Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin | Q41945836 | ||
Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. | Q44243477 | ||
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons | Q45747957 | ||
Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group | Q45752474 | ||
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection | Q46180015 | ||
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells | Q46976285 | ||
Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. | Q51601960 | ||
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate | Q57997600 | ||
Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges | Q59661537 | ||
Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody | Q73030181 | ||
Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop | Q74019913 | ||
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland | Q76383446 | ||
Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals | Q81109508 | ||
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA | Q81487908 | ||
Sublingual immunization induces broad-based systemic and mucosal immune responses in mice | Q81587050 | ||
Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits | Q82875885 | ||
Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, oligoclonal, and affinity-matured gut IgA responses | Q84564316 | ||
Preparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administration | Q85023007 | ||
Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells | Q87003088 | ||
P304 | page(s) | 63 | |
P577 | publication date | 2017-02-01 | |
P1433 | published in | Frontiers in Immunology | Q27723748 |
P1476 | title | Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates | |
P478 | volume | 8 |
Q63246465 | HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge |
Q88502282 | Linking stress and immunity: Immunoglobulin A as a non-invasive physiological biomarker in animal welfare studies |
Q57282350 | Oral co-administration of an intramuscular DNA/ Modified Vaccinia Ankara vaccine for simian immunodeficiency virus is associated with better control of infection in orally exposed infant macaques |
Search more.